Non-rituximab-RIC N = 1022 | Rituximab-containing RIC N = 379 | ||||
---|---|---|---|---|---|
Outcomes | N eval | Prob (95%CI) | N eval | Prob (95%CI) | p value |
ANC recovery >500/uL | 1013 | 379 | |||
28 days | 97 (96–98)% | 98 (96–99)% | 0.51 | ||
100 days | 99 (98–99)% | 99 (97–100)% | 0.99 | ||
Platelet recovery ≥ 20/uL | 986 | 378 | |||
28 days | 90 (88–92)% | 90 (87–93)% | 0.66 | ||
100 days | 96 (94–97)% | 96 (93–97)% | 0.79 | ||
Acute GVHD (II IV) | 1004 | 377 | |||
180 days | 37 (34–40)% | 43 (38–48)% | 0.03 | ||
Acute GVHD (III IV) | 1004 | 377 | |||
180 days | 13 (11–16)% | 16 (12–19)% | 0.29 | ||
Chronic GVHD | 982 | 369 | |||
1 year | 44 (41–48)% | 41 (36–47)% | 0.32 | ||
2 years | 53 (50–57)% | 53 (47–58)% | 0.79 | ||
NRM | 988 | 367 | |||
1 year | 14 (12–16)% | 13 (10–17)% | 0.78 | ||
3 years | 21 (18–24)% | 20 (16–24)% | 0.68 | ||
Relapse/progression | 988 | 367 | |||
1 year | 26 (23–29)% | 19 (15–23)% | 0.004 | ||
3 years | 32 (29–35)% | 24 (20–29)% | 0.005 | ||
PFS | 988 | 367 | |||
1 year | 60 (57–63)% | 68 (63–72)% | 0.007 | ||
3 years | 47 (44–50)% | 56 (51–61)% | 0.005 | ||
Mortality (inverse of OS) | 1022 | 379 | |||
1 year | 70 (67–73)% | 76 (71–80)% | 0.04 | ||
3 years | 56 (53–59)% | 64 (59–68)% | 0.01 |